Transcatheter pulmonary valve also
referred to as human transcatheter pulmonary valve, as defined by WHO, is a
biological preparation that improves immunity to a particular disease. It
contains an agent that resembles a disease causing microorganism and is often
made from weakened or killed forms of the microbe, its toxins or one of its
surface proteins. Human body has natural ability to learn about eliminating all
sort of germs or microbes that cause diseases. Transcatheter pulmonary valve
utilizes that ability of the body to enable it to protect itself, from those
microbes, which have attacked it before. Typically, transcatheter pulmonary
valve are administered through injections, orally and sprayed into the nose.
Human transcatheter pulmonary valve is of two technologys such as preventable
and therapeutic transcatheter pulmonary valve. The preventable human transcatheter
pulmonary valve is used in children and adults to immunize the individuals
against pulmonary atresias such as influenza, diphtheria, hepatitis,
pneumococcal diseases, and meningococcal diseases among others.
Transcatheter pulmonary valve
also known as percutaneous or catheter-based pulmonary valve. Transcatheter
pulmonary valve replacement is a minimally invasive heart surgery that involves
the positioning and placement of a pulmonary valve prosthesis via a catheter
inserted into a vein. Transcatheter pulmonary valve are delivery by system
which, is a thin, hollow, and long tube (catheter) that delivers the
transcatheter pulmonary valve into the heart without open heart surgery while
the heart is beating.
Figure 1: Global Transcatheter Pulmonary Valve Market by Value 2015 –
The global transcatheter
pulmonary valve market was worth USD 33.97 million in 2016 and it is projected
to reach USD 50.92 million in 2023, expanding at a CAGR of 6.2% between 2017
and 2023. High prevalence of various cardiovascular disorders, growing
geriatric population with heart valve diseases such as pulmonary stenosis,
pulmonary regurgitation, and others are the primary factor driving the growth
in the global market for transcatheter pulmonary valve. Moreover, the
government support for the development of transcatheter pulmonary valve is
likely to augment the growth in the market over the next six years. Moreover,
and increasing investments in the research and development of new transcatheter
pulmonary valve is expected to accelerate the growth in the transcatheter
pulmonary valve market over the forecast period. On the other hand, high cost
associated with development of transcatheter pulmonary valve is the primary
restraining factor hampering the growth in the market over the forecast period.
Government initiatives in emerging markets and economic development in emerging
markets of Asia, Latin America and Africa to augment the healthcare expenditure
per capita and new transcatheter pulmonary valve in pipeline are likely to
provide opportunities for the companies operating in the global transcatheter
pulmonary valve market.
The report on global
transcatheter pulmonary valve market covers segments such as application,
technology, end-use, and raw material. The application segments include
pulmonary atresia, cardiac anomaly, pulmonary stenosis, tetralogy of fallot,
truncus arteriosus, pulmonary regurgitation and others. On the basis of
technology, the global transcatheter pulmonary valve market is categorized into
self-expanded transcatheter valve and balloon-expanded transcatheter valve.
Furthermore, on the basis of end-use the transcatheter pulmonary valve market
is segmented as pediatric and adult. On the basis of raw material, the
transcatheter pulmonary valve market is segmented as tissue engineered
transcatheter valve and synthetic transcatheter valve.
The report provides regional
analysis covering geographies such as North America, Europe, Asia-Pacific, and
Rest of the World. In this section the key trends and market size for each
geography is provided over the period of 2015 – 2023.
Figure 2: Global Transcatheter Pulmonary Valve Market by Region, CAGR
North America accounted for the
largest market share in the global transcatheter pulmonary valve market in 2015
and 2016. The growth in the region is mainly driven by large scale production
and consumption of transcatheter pulmonary valve in the U.S. Asia-Pacific is
expected to growth at the highest CAGR of X.X% over the forecast period.
The report provides profiles of
the companies in the global transcatheter pulmonary valve market such as,
Colibri Heart Valve, LLC, Cryolife, Inc., LivaNova PLC.(Sorin Group), Venus
Medtech, Xeltis, SYMETIS SA, St. Jude Medical, Medtronic, Edward Lifesciences
Corporation, and Direct Flow Medical, Inc.
The report provides deep insights
on demand forecasts, market trends and micro and macro indicators. In addition,
this report provides insights on the factors that are driving and restraining
the global transcatheter pulmonary valve market. Moreover, IGR-Growth Matrix
analysis given in the report brings an insight on the investment areas that
existing or new market players can consider. The report provides insights into
the market using analytical tools such as Porter’s five forces analysis and DRO
analysis of transcatheter pulmonary valve market.
Moreover, the study highlights current
market trends and provides forecast from 2017 to 2023. We also have highlighted
future trends in the transcatheter pulmonary valve market that will impact the
demand during the forecast period. Moreover, the competitive analysis given in
each regional market brings an insight on the market share of the leading
players. Additionally, the analysis highlights rise and fall in the market
shares of the key players in the market. This report will help manufacturers,
suppliers and distributors of the transcatheter pulmonary valve market to
understand the present and future trends in this market and formulate their